The need for new antimicrobials is increasingly urgent. The rate of multidrug resistant pathogens continues to increase leading to significant morbidity and mortality throughout the world. Furthermore, the current pipeline for new antimicrobials remains very narrow. The Infectious Diseases Society of America has identified in their """"""""Bad Bugs, No Drugs"""""""" campaign, a group of pathogens that have become increasingly resistant to current antibiotics. This group includes the Gram-negative pathogens Acinetobacter baumannii and Escherichia coli. A new paradigm in antibiotic discovery and design has recently been shown effective against numerous bacteria. This new approach is based on a platform technology called peptide-phosphorodiamidate mopholino oligomers (PPMOs). PPMOs are synthetic DNA mimics that bind to RNA in a sequence-specific, antisense manner and inhibit expression of essential bacterial genes. PPMOs have already been used successfully to kill a variety of bacterial pathogens including the Gram-negative bacteria Escherichia coli, Salmonella typhimurium, Burkholderia cepacia complex and Acinetobacter baumannii. PPMOS are bactericidal in culture, and reduce bacteremia and improve survival in animal models of infection. PPMOs are more potent than many traditional antibiotics such as ampicillin. The goal of this project is to develop PPMOs for therapeutic use against the multidrug resistant pathogens Escherichia coli and Acinetobacter baumannii.
The specific aims are to design, produce and screen PPMOS against various gene targets in the multidrug-resistant pathogens E. coli and A. baumannii. The experimental approach is to target genes in pathways that are known or suspected to be essential for the growth of the organism, including genes for biosynthesis of lipopolysaccharide, peptidoglycan, and fatty acids. Another approach will be to use PPMOs as adjunctive therapies and target specific antibiotic resistance mechanisms in order to restore susceptibility to currently used antibiotics. This technology provides a methodological advantage because many PPMOs can be rapidly synthesized and simultaneously tested against numerous targets. This allows for the possibility of targeting multiple genes in a single organism or the development of cocktails of PPMOs that target multiple pathogens. This project will identify lead target PPMOs in E. coli and A. baumannii that can be moved forward to pre- clinical and clinical studies.
Multidrug resistance among Gram-negative bacterial pathogens is becoming increasingly frequent. We propose to utilize a novel anti-sense technology to rapidly develop and screen therapeutic compounds targeting essential genes as well as antibiotic resistance mechanisms in the multidrug resistant pathogens Escherichia coli and Acinetobacter baumannii. Because of the novelty of these antisense antibacterial compounds, they should be effective against bacteria that are resistant to existing antibiotics.
|Sully, Erin K; Geller, Bruce L; Li, Lixin et al. (2017) Peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) restores carbapenem susceptibility to NDM-1-positive pathogens in vitro and in vivo. J Antimicrob Chemother 72:782-790|
|Daly, Seth M; Sturge, Carolyn R; Felder-Scott, Christina F et al. (2017) MCR-1 Inhibition with Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers Restores Sensitivity to Polymyxin in Escherichia coli. MBio 8:|
|Ayhan, Dilay Hazal; Tamer, Yusuf Talha; Akbar, Mohammed et al. (2016) Sequence-Specific Targeting of Bacterial Resistance Genes Increases Antibiotic Efficacy. PLoS Biol 14:e1002552|
|Sully, Erin K; Geller, Bruce L (2016) Antisense antimicrobial therapeutics. Curr Opin Microbiol 33:47-55|
|Geller, Bruce L; Marshall-Batty, Kimberly; Schnell, Frederick J et al. (2013) Gene-silencing antisense oligomers inhibit acinetobacter growth in vitro and in vivo. J Infect Dis 208:1553-60|